Global Scleroderma Market Report 2024

Scleroderma Global Market Report 2024 – By Treatment (Medication, Surgery, Other Treatments), By Indication (Systemic Scleroderma, Localized Scleroderma), By End User (Hospital, Pharmaceutical Stores, Other End Users) – Market Size, Trends, And Global Forecast 2024-2033

Scleroderma Global Market Report 2024

Starting Price : $5000.00 $4000.00 | Pages : | Published : October 2024 | Delivery Time: 2-3 business days | Format : pdf

Need assistance or more information before the purchase?

Enquire Before Buying
Scleroderma Global Market Report 2024

Proud Members Of

checkslacipN checkaoirsN checkscipN

Scleroderma Market Definition

Scleroderma is a rare, chronic autoimmune disease characterized by the abnormal growth of collagen, a protein that forms the structure of the skin and other tissues. The different treatments cure or halt excessive collagen production, effectively manage symptoms, and reduce the risk of complications associated with scleroderma.

The main treatments of scleroderma include medication, surgery, and others. Medication refers to substances, usually in the form of drugs or pharmaceuticals, that are used to prevent, treat, or manage medical conditions, diseases, or symptoms. It is indicated for the treatment of systemic scleroderma and localized scleroderma by hospitals, pharmaceutical stores, and others.

Scleroderma Market Segmentation

The scleroderma market covered in this report is segmented –

1) By Treatment: Medication, Surgery, Other Treatments

2) By Indication: Systemic Scleroderma, Localized Scleroderma

3) By End User: Hospital, Pharmaceutical Stores, Other End Users

Global Scleroderma Market Size 2023 to 2028: Graph

Scleroderma Market Size 2024 And Growth Rate

The scleroderma market size has grown strongly in recent years. It will grow from $2.15 billion in 2023 to $2.31 billion in 2024 at a compound annual growth rate (CAGR) of 7.4%. The growth in the historic period can be attributed to advances in diagnosis, immunological research, therapeutic developments, awareness and education, genetic studies.

Scleroderma Market Growth Forecast

The scleroderma market size is expected to see strong growth in the next few years. It will grow to $2.97 billion in 2028 at a compound annual growth rate (CAGR) of 6.5%. The growth in the forecast period can be attributed to biological therapies, precision medicine, stem cell therapies, genomic and biomarker research, global collaborations. Major trends in the forecast period include digital health solutions, focus on microbiome, patient-centric care, regenerative medicine, health equity and access.

Scleroderma Market Driver: Rising Scleroderma Cases Propel Therapeutics Demand

The greater prevalence of scleroderma is driving the scleroderma market going forward. Scleroderma is a chronic autoimmune disease characterized by the abnormal growth of collagen, a protein that forms the structure of skin and other tissues. An unregulated immune response, possibly triggered by various environmental factors, leads to the development of this condition. As the number of cases rises, the importance of improved diagnosis and treatment becomes evident. Scleroderma therapeutics are crucial to managing illness and alleviating symptoms by regulating the immune response and mitigating exposure to environmental risk factors. For instance, in June 2022, according to Karger Publishers, a Switzerland-based publisher of peer-reviewed journals, 19,000 people had scleroderma in the UK and 2.5 million people worldwide. Furthermore, in July 2021, a research article published by Oxford Academic Press, a university press affiliated with the University of Oxford in the UK, revealed that the global prevalence of scleroderma was 17.6 cases per 100,000 people and the incidence rate was 1.4 cases per 100,000 person-years. As a result, the greater prevalence of scleroderma is driving the scleroderma market.

Scleroderma Market Driver: The Scleroderma Market's Impact On Toxin Exposure

The exposure to toxins is driving the scleroderma market forward. Exposure to toxins refers to the contact or ingestion of harmful substances that can adversely affect biological systems. The scleroderma market plays a pivotal role in addressing exposure to toxins by advancing research, developing targeted therapies, and enhancing patient care for those affected by scleroderma, a condition with potential environmental and genetic triggers. For instance, in January 2023, according to the report by Poison Control, US-based, a national poison control system that provides expert advice on poison exposure to the public, over 2.08 million human poison exposures were reported, with 75.5% being unintentional, and children under six accounting for 37.0 poison exposures per 1,000 children in 2021. In contrast, the previous year, 2020, saw 83% of reported poison exposures deemed nontoxic by U.S. poison centers. As a result, the exposure to toxins is driving the scleroderma market.

Global Scleroderma Market Major Players

Major companies operating in the scleroderma market report are Pfizer Inc., Johnson And Johnson Inc., F. Hoffmann-La Roche AG, Abbvie Inc., Bayer AG, Novartis AG, Merck And Co. Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., GSK plc, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Aspen Pharmacare Holdings Limited, Boehringer Ingelheim International GmbH, Principia Biopharma Corp, aTyr Pharma Inc., Cumberland Pharmaceuticals Inc., Kadmon Holdings Inc., Emerald Health Pharmaceuticals Inc., FibroGen Inc., Argentis Pharmaceuticals LLC, Corbus Pharmaceuticals Holdings Inc., Celgene Corporation, Actelion Pharmaceuticals Inc., H.A.C. Pharma

Global Scleroderma Market Trend: Novel Treatments Drive Scleroderma Market Growth

Developing novel treatments is a key trend gaining popularity in the scleroderma market. Major companies in the scleroderma market are developing novel drugs to manage the symptoms and sustain their position in the market. For instance, in April 2022, Tyr Pharma Inc., a US-based biotherapeutics manufacturer, received regulatory approval for its novel systemic sclerosis-related interstitial lung disease drug efzofitimod from the US Food and Drug Administration, a US-based health regulatory agency. The new drug is a First-in-class immunomodulator to downregulate and control the immune response by modulating the neuropilin-2 (NRP2) receptor to reduce symptoms of scleroderma. Additionally, Efzofitimod also targets the same immune cells responsible for the pathology of SSc-ILD (interstitial lung disease associated with systemic sclerosis) and pulmonary sarcoidosis, leading to reduced pro-inflammatory markers in a clinical study with patients suffering from pulmonary sarcoidosis.

Global Scleroderma Market Trend: Key Strategies Of Major Companies In The Scleroderma Market

Major companies operating in the scleroderma market are focusing on product launches, such as a clinical trial platform, to advance treatments for scleroderma and identify agents that should progress from Phase IIb to Phase III. A clinical trial platform is a comprehensive infrastructure and framework facilitating the simultaneous evaluation of multiple therapies or interventions in a standardized manner across various clinical trials. For instance, in August 2023, The Scleroderma Research Foundation (SRF), a US-based non-profit organization that funds research into scleroderma, launched CONQUEST, a groundbreaking clinical trial platform. This launch boasts a global reach with enrolment across 130 centers in 22 countries, employing a master protocol for the evaluation of multiple therapies. This groundbreaking initiative is poised to significantly impact the scleroderma market by expediting the development and approval of effective therapies through its collaborative and efficient approach to clinical evaluation.

Scleroderma Market Merger And Acquisition: Sanofi's Commitment To Serve And Grow Customer Base Through Kadmon Acquisition

In November 2021, Sanofi S.A., a France-based pharmaceutical company, acquired Kadmon Holdings for approximately $1.9 billion. Through this acquisition, Sanofi S.A. aims to expand its medicine business and better serve its customer base. Further, Sanofi plans to continue the development of Belumosudil, Kadmon's investigational therapy, to treat diffuse cutaneous systemic sclerosis (dcSSc). Kadmon Holdings is a US-based biopharmaceutical company that discovers, develops, and markets transformative medicines for disease areas with significant unmet medical needs.

Regional Outlook For The Global Scleroderma Market

North America was the largest region in the scleroderma market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the scleroderma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the scleroderma market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The scleroderma market consists of revenues earned by entities by providing dilation of blood vessels, immunosuppressants, relieving pain, and reducing infection. The market value includes the value of related goods sold by the service provider or included within the service offering. The scleroderma market also includes the sales of methotrexate, anti-thymocyte globulin, mycophenolate mofetil, and cyclophosphamide. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

The scleroderma market research report is one of a series of new reports from The Business Research Company that provides scleroderma market statistics, including scleroderma industry global market size, regional shares, competitors with a scleroderma market share, detailed scleroderma market segments, market trends and opportunities, and any further data you may need to thrive in the scleroderma industry. This scleroderma market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Scleroderma Market Report Forecast And Analysis
Report AttributeDetails
Market Size Value In 2024 $2.31 billion
Revenue Forecast In 2033 $2.97 billion
Growth Rate CAGR of 6.5% from 2024 to 2033
Base Year For Estimation 2023
Actual Estimates/Historical Data 2018-2023
Forecast Period 2024 - 2028 - 2033
Market Representation Revenue in USD Billion and CAGR from 2024 to 2033
Segments Covered 1) By Treatment: Medication, Surgery, Other Treatments
2) By Indication: Systemic Scleroderma, Localized Scleroderma
3) By End User: Hospital, Pharmaceutical Stores, Other End Users
Regional Scope Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Country Scope The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Additional countries that can be covered in the report for an additional fee: Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, New Zealand, Mexico, Chile, Argentina, Colombia, Peru, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Czech Republic, Poland, Romania, Ukraine, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.
Key Companies Profiled Pfizer Inc.; Johnson And Johnson Inc.; F. Hoffmann-La Roche AG; Abbvie Inc.; Bayer AG; Novartis AG; Merck And Co. Inc.; Sanofi S.A.; Bristol-Myers Squibb Company; AstraZeneca plc; Takeda Pharmaceutical Company Limited; Eli Lilly and Company; Gilead Sciences Inc.; Amgen Inc.; GSK plc; Teva Pharmaceutical Industries Ltd.; Astellas Pharma Inc.; Aspen Pharmacare Holdings Limited; Boehringer Ingelheim International GmbH; Principia Biopharma Corp; aTyr Pharma Inc.; Cumberland Pharmaceuticals Inc.; Kadmon Holdings Inc.; Emerald Health Pharmaceuticals Inc.; FibroGen Inc.; Argentis Pharmaceuticals LLC; Corbus Pharmaceuticals Holdings Inc.; Celgene Corporation; Actelion Pharmaceuticals Inc.; H.A.C. Pharma
Customization ScopeRequest for Sample
Pricing And Purchase OptionsExplore Purchase Options

    Table Of Contents

    1. Executive Summary

    2. Scleroderma Market Characteristics

    3. Scleroderma Market Trends And Strategies

    4. Scleroderma Market - Macro Economic Scenario

    4.1. Impact Of High Inflation On The Market

    4.2. Ukraine-Russia War Impact On The Market

    4.3. COVID-19 Impact On The Market

    5. Global Scleroderma Market Size and Growth

    5.1. Global Scleroderma Market Drivers and Restraints

    5.1.1. Drivers Of The Market

    5.1.2. Restraints Of The Market

    5.2. Global Scleroderma Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)

    5.3. Global Scleroderma Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

    6. Scleroderma Market Segmentation

    6.1. Global Scleroderma Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    Medication

    Surgery

    Other Treatments

    6.2. Global Scleroderma Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    Systemic Scleroderma

    Localized Scleroderma

    6.3. Global Scleroderma Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    Hospital

    Pharmaceutical Stores

    Other End Users

    7. Scleroderma Market Regional And Country Analysis

    7.1. Global Scleroderma Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    7.2. Global Scleroderma Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    8. Asia-Pacific Scleroderma Market

    8.1. Asia-Pacific Scleroderma Market Overview

    Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

    8.2. Asia-Pacific Scleroderma Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    8.3. Asia-Pacific Scleroderma Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    8.4. Asia-Pacific Scleroderma Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    9. China Scleroderma Market

    9.1. China Scleroderma Market Overview

    9.2. China Scleroderma Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

    9.3. China Scleroderma Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

    9.4. China Scleroderma Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

    10. India Scleroderma Market

    10.1. India Scleroderma Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    10.2. India Scleroderma Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    10.3. India Scleroderma Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    11. Japan Scleroderma Market

    11.1. Japan Scleroderma Market Overview

    11.2. Japan Scleroderma Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    11.3. Japan Scleroderma Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    11.4. Japan Scleroderma Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    12. Australia Scleroderma Market

    12.1. Australia Scleroderma Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    12.2. Australia Scleroderma Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    12.3. Australia Scleroderma Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    13. Indonesia Scleroderma Market

    13.1. Indonesia Scleroderma Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    13.2. Indonesia Scleroderma Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    13.3. Indonesia Scleroderma Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    14. South Korea Scleroderma Market

    14.1. South Korea Scleroderma Market Overview

    14.2. South Korea Scleroderma Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    14.3. South Korea Scleroderma Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    14.4. South Korea Scleroderma Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    15. Western Europe Scleroderma Market

    15.1. Western Europe Scleroderma Market Overview

    15.2. Western Europe Scleroderma Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    15.3. Western Europe Scleroderma Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    15.4. Western Europe Scleroderma Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    16. UK Scleroderma Market

    16.1. UK Scleroderma Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    16.2. UK Scleroderma Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    16.3. UK Scleroderma Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    17. Germany Scleroderma Market

    17.1. Germany Scleroderma Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    17.2. Germany Scleroderma Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    17.3. Germany Scleroderma Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    18. France Scleroderma Market

    18.5. France Scleroderma Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    18.6. France Scleroderma Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    18.7. France Scleroderma Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    19. Italy Scleroderma Market

    19.9. Italy Scleroderma Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    19.10. Italy Scleroderma Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    19.11. Italy Scleroderma Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    20. Spain Scleroderma Market

    20.13. Spain Scleroderma Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    20.14. Spain Scleroderma Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    20.15. Spain Scleroderma Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    21. Eastern Europe Scleroderma Market

    21.1. Eastern Europe Scleroderma Market Overview

    21.2. Eastern Europe Scleroderma Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    21.3. Eastern Europe Scleroderma Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    21.4. Eastern Europe Scleroderma Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    22. Russia Scleroderma Market

    22.1. Russia Scleroderma Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    22.2. Russia Scleroderma Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    22.3. Russia Scleroderma Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    23. North America Scleroderma Market

    23.1. North America Scleroderma Market Overview

    23.2. North America Scleroderma Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    23.3. North America Scleroderma Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    23.4. North America Scleroderma Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    24. USA Scleroderma Market

    24.1. USA Scleroderma Market Overview

    24.2. USA Scleroderma Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    24.3. USA Scleroderma Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    24.4. USA Scleroderma Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    25. Canada Scleroderma Market

    25.1. Canada Scleroderma Market Overview

    25.2. Canada Scleroderma Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    25.3. Canada Scleroderma Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    25.4. Canada Scleroderma Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    26. South America Scleroderma Market

    26.1. South America Scleroderma Market Overview

    26.2. South America Scleroderma Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    26.3. South America Scleroderma Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    26.4. South America Scleroderma Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    27. Brazil Scleroderma Market

    27.1. Brazil Scleroderma Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    27.2. Brazil Scleroderma Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    27.3. Brazil Scleroderma Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    28. Middle East Scleroderma Market

    28.1. Middle East Scleroderma Market Overview

    28.2. Middle East Scleroderma Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    28.3. Middle East Scleroderma Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    28.4. Middle East Scleroderma Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    29. Africa Scleroderma Market

    29.1. Africa Scleroderma Market Overview

    29.2. Africa Scleroderma Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    29.3. Africa Scleroderma Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    29.4. Africa Scleroderma Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    30. Scleroderma Market Competitive Landscape And Company Profiles

    30.1. Scleroderma Market Competitive Landscape

    30.2. Scleroderma Market Company Profiles

    30.2.1. Pfizer Inc.

    30.2.1.1. Overview

    30.2.1.2. Products and Services

    30.2.1.3. Strategy

    30.2.1.4. Financial Performance

    30.2.2. Johnson And Johnson Inc.

    30.2.2.1. Overview

    30.2.2.2. Products and Services

    30.2.2.3. Strategy

    30.2.2.4. Financial Performance

    30.2.3. F. Hoffmann-La Roche AG

    30.2.3.1. Overview

    30.2.3.2. Products and Services

    30.2.3.3. Strategy

    30.2.3.4. Financial Performance

    30.2.4. AbbVie Inc.

    30.2.4.1. Overview

    30.2.4.2. Products and Services

    30.2.4.3. Strategy

    30.2.4.4. Financial Performance

    30.2.5. Bayer AG

    30.2.5.1. Overview

    30.2.5.2. Products and Services

    30.2.5.3. Strategy

    30.2.5.4. Financial Performance

    31. Scleroderma Market Other Major And Innovative Companies

    31.1. Novartis AG

    31.2. Merck And Co. Inc.

    31.3. Sanofi S.A.

    31.4. Bristol-Myers Squibb Company

    31.5. AstraZeneca plc

    31.6. Takeda Pharmaceutical Company Limited

    31.7. Eli Lilly and Company

    31.8. Gilead Sciences Inc.

    31.9. Amgen Inc.

    31.10. GSK plc

    31.11. Teva Pharmaceutical Industries Ltd.

    31.12. Astellas Pharma Inc.

    31.13. Aspen Pharmacare Holdings Limited

    31.14. Boehringer Ingelheim International GmbH

    31.15. Principia Biopharma Corp

    32. Global Scleroderma Market Competitive Benchmarking

    33. Global Scleroderma Market Competitive Dashboard

    34. Key Mergers And Acquisitions In The Scleroderma Market

    35. Scleroderma Market Future Outlook and Potential Analysis

    35.1 Scleroderma Market In 2028 - Countries Offering Most New Opportunities

    35.2 Scleroderma Market In 2028 - Segments Offering Most New Opportunities

    35.3 Scleroderma Market In 2028 - Growth Strategies

    35.3.1 Market Trend Based Strategies

    35.3.2 Competitor Strategies

    36. Appendix

    36.1. Abbreviations

    36.2. Currencies

    36.3. Historic And Forecast Inflation Rates

    36.4. Research Inquiries

    36.5. The Business Research Company

    36.6. Copyright And Disclaimer

List Of Tables

    Table 1: Global Historic Market Growth, 2018-2023, $ Billion
  • Table 2: Global Forecast Market Growth, 2023-2028F, 2033F, $ Billion
  • Table 3: Global Scleroderma Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 4: Global Scleroderma Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 5: Global Scleroderma Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 6: Global Scleroderma Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 7: Global Scleroderma Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 8: Asia-Pacific, Scleroderma Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 9: Asia-Pacific, Scleroderma Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 10: Asia-Pacific, Scleroderma Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 11: China, Scleroderma Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 12: China, Scleroderma Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 13: China, Scleroderma Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 14: India, Scleroderma Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 15: India, Scleroderma Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 16: India, Scleroderma Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 17: Japan, Scleroderma Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 18: Japan, Scleroderma Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 19: Japan, Scleroderma Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 20: Australia, Scleroderma Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 21: Australia, Scleroderma Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 22: Australia, Scleroderma Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 23: Indonesia, Scleroderma Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 24: Indonesia, Scleroderma Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 25: Indonesia, Scleroderma Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 26: South Korea, Scleroderma Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 27: South Korea, Scleroderma Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 28: South Korea, Scleroderma Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 29: Western Europe, Scleroderma Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 30: Western Europe, Scleroderma Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 31: Western Europe, Scleroderma Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 32: UK, Scleroderma Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 33: UK, Scleroderma Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 34: UK, Scleroderma Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 35: Germany, Scleroderma Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 36: Germany, Scleroderma Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 37: Germany, Scleroderma Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 38: France, Scleroderma Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 39: France, Scleroderma Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 40: France, Scleroderma Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 41: Italy, Scleroderma Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 42: Italy, Scleroderma Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 43: Italy, Scleroderma Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 44: Spain, Scleroderma Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 45: Spain, Scleroderma Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 46: Spain, Scleroderma Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 47: Eastern Europe, Scleroderma Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 48: Eastern Europe, Scleroderma Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 49: Eastern Europe, Scleroderma Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 50: Russia, Scleroderma Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 51: Russia, Scleroderma Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 52: Russia, Scleroderma Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 53: North America, Scleroderma Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 54: North America, Scleroderma Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 55: North America, Scleroderma Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 56: USA, Scleroderma Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 57: USA, Scleroderma Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 58: USA, Scleroderma Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 59: Canada, Scleroderma Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 60: Canada, Scleroderma Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 61: Canada, Scleroderma Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 62: South America, Scleroderma Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 63: South America, Scleroderma Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 64: South America, Scleroderma Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 65: Brazil, Scleroderma Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 66: Brazil, Scleroderma Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 67: Brazil, Scleroderma Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 68: Middle East, Scleroderma Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 69: Middle East, Scleroderma Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 70: Middle East, Scleroderma Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 71: Africa, Scleroderma Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 72: Africa, Scleroderma Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 73: Africa, Scleroderma Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 74: Pfizer Inc. Financial Performance
  • Table 75: Johnson And Johnson Inc. Financial Performance
  • Table 76: F. Hoffmann-La Roche AG Financial Performance
  • Table 77: AbbVie Inc. Financial Performance
  • Table 78: Bayer AG Financial Performance

List Of Figures

    Figure 1: Global Historic Market Growth, 2018-2023, $ Billion
  • Figure 2: Global Forecast Market Growth, 2023-2028F, 2033F, $ Billion
  • Figure 3: Global Scleroderma Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 4: Global Scleroderma Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 5: Global Scleroderma Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 6: Global Scleroderma Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 7: Global Scleroderma Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 8: Asia-Pacific, Scleroderma Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 9: Asia-Pacific, Scleroderma Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 10: Asia-Pacific, Scleroderma Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 11: China, Scleroderma Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 12: China, Scleroderma Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 13: China, Scleroderma Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 14: India, Scleroderma Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 15: India, Scleroderma Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 16: India, Scleroderma Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 17: Japan, Scleroderma Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 18: Japan, Scleroderma Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 19: Japan, Scleroderma Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 20: Australia, Scleroderma Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 21: Australia, Scleroderma Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 22: Australia, Scleroderma Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 23: Indonesia, Scleroderma Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 24: Indonesia, Scleroderma Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 25: Indonesia, Scleroderma Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 26: South Korea, Scleroderma Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 27: South Korea, Scleroderma Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 28: South Korea, Scleroderma Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 29: Western Europe, Scleroderma Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 30: Western Europe, Scleroderma Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 31: Western Europe, Scleroderma Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 32: UK, Scleroderma Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 33: UK, Scleroderma Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 34: UK, Scleroderma Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 35: Germany, Scleroderma Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 36: Germany, Scleroderma Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 37: Germany, Scleroderma Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 38: France, Scleroderma Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 39: France, Scleroderma Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 40: France, Scleroderma Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 41: Italy, Scleroderma Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 42: Italy, Scleroderma Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 43: Italy, Scleroderma Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 44: Spain, Scleroderma Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 45: Spain, Scleroderma Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 46: Spain, Scleroderma Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 47: Eastern Europe, Scleroderma Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 48: Eastern Europe, Scleroderma Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 49: Eastern Europe, Scleroderma Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 50: Russia, Scleroderma Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 51: Russia, Scleroderma Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 52: Russia, Scleroderma Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 53: North America, Scleroderma Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 54: North America, Scleroderma Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 55: North America, Scleroderma Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 56: USA, Scleroderma Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 57: USA, Scleroderma Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 58: USA, Scleroderma Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 59: Canada, Scleroderma Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 60: Canada, Scleroderma Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 61: Canada, Scleroderma Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 62: South America, Scleroderma Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 63: South America, Scleroderma Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 64: South America, Scleroderma Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 65: Brazil, Scleroderma Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 66: Brazil, Scleroderma Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 67: Brazil, Scleroderma Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 68: Middle East, Scleroderma Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 69: Middle East, Scleroderma Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 70: Middle East, Scleroderma Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 71: Africa, Scleroderma Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 72: Africa, Scleroderma Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 73: Africa, Scleroderma Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 74: Pfizer Inc. Financial Performance
  • Figure 75: Johnson And Johnson Inc. Financial Performance
  • Figure 76: F. Hoffmann-La Roche AG Financial Performance
  • Figure 77: AbbVie Inc. Financial Performance
  • Figure 78: Bayer AG Financial Performance
View Report
View Report
View Report
View Report
View Report
View Report
View Report
View Report

Frequently Asked Questions

What is the definition of the scleroderma market?

Scleroderma is a rare, chronic autoimmune disease characterized by the abnormal growth of collagen, a protein that forms the structure of the skin and other tissues. The different treatments cure or halt excessive collagen production, effectively manage symptoms, and reduce the risk of complications associated with scleroderma. For further insights on the scleroderma market, request a sample here

How will the scleroderma market drivers and restraints affect the scleroderma market dynamics? What forces will shape the scleroderma industry going forward?

The scleroderma market major growth driver - Rising Scleroderma Cases Propel Therapeutics Demand. For further insights on the scleroderma market, request a sample here

What is the forecast market size or the forecast market value of the scleroderma market?

The scleroderma market size has grown strongly in recent years. It will grow from $2.15 billion in 2023 to $2.31 billion in 2024 at a compound annual growth rate (CAGR) of 7.4%. The growth in the historic period can be attributed to advances in diagnosis, immunological research, therapeutic developments, awareness and education, genetic studies. The scleroderma market size is expected to see strong growth in the next few years. It will grow to $2.97 billion in 2028 at a compound annual growth rate (CAGR) of 6.5%. The growth in the forecast period can be attributed to biological therapies, precision medicine, stem cell therapies, genomic and biomarker research, global collaborations. Major trends in the forecast period include digital health solutions, focus on microbiome, patient-centric care, regenerative medicine, health equity and access. For further insights on the scleroderma market, request a sample here

How is the scleroderma market segmented?

The scleroderma market is segmented
1) By Treatment: Medication, Surgery, Other Treatments
2) By Indication: Systemic Scleroderma, Localized Scleroderma
3) By End User: Hospital, Pharmaceutical Stores, Other End UsersFor further insights on the scleroderma market,
request a sample here

Which region has the largest share of the scleroderma market? What are the other regions covered in the report?

North America was the largest region in the scleroderma market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the scleroderma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa For further insights on the scleroderma market, request a sample here.

Who are the major players in the scleroderma market?

Major companies operating in the scleroderma market report are Pfizer Inc., Johnson And Johnson Inc., F. Hoffmann-La Roche AG, Abbvie Inc., Bayer AG, Novartis AG, Merck And Co. Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., GSK plc, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Aspen Pharmacare Holdings Limited, Boehringer Ingelheim International GmbH, Principia Biopharma Corp, aTyr Pharma Inc., Cumberland Pharmaceuticals Inc., Kadmon Holdings Inc., Emerald Health Pharmaceuticals Inc., FibroGen Inc., Argentis Pharmaceuticals LLC, Corbus Pharmaceuticals Holdings Inc., Celgene Corporation, Actelion Pharmaceuticals Inc., H.A.C. Pharma For further insights on the scleroderma market, request a sample here.

What are the key trends in the scleroderma market?

Major trend in the scleroderma market - Novel Treatments Drive Scleroderma Market Growth. For further insights on the scleroderma market, request a sample here.

What are the major opportunities in the scleroderma market? What are the strategies for the scleroderma market?

For detailed insights on the major opportunities and strategies in the scleroderma market, request a sample here.

How does the scleroderma market relate to the overall economy and other similar markets?

For detailed insights on scleroderma market's relation to the overall economy and other similar markets, request a sample here.

What are the latest mergers and acquisitions in the scleroderma industry?

For detailed insights on the mergers and acquisitions in the scleroderma industry, request a sample here.

What are the key dynamics influencing the scleroderma market growth? SWOT analysis of the scleroderma market.

For detailed insights on the key dynamics influencing the scleroderma market growth and SWOT analysis of the scleroderma industry, request a sample here.